Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Clinical Endocrinology News Digital Network Available data on a possible link between antihyperglycemic drugs and an increased risk of pancreatitis and certain cancers do not justify making changes in clinical practice, according to a consensus statement on diabetes and cancer released by the ...
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Clinical Endocrinology News Digital Network Available data on a possible link between antihyperglycemic drugs and an increased risk of pancreatitis and certain cancers do not justify making changes in clinical practice, according to a consensus statement on diabetes and cancer released by the ...
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Clinical Endocrinology News Digital Network Available data on a possible link between antihyperglycemic drugs and an increased risk of pancreatitis and certain cancers do not justify making changes in clinical practice, according to a consensus statement on diabetes and cancer released by the ... and more »
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
Family Practice News Digital Network The cardiac safety of rosiglitazone, a thiazolidinedione (TZD) marketed as Avandia by GlaxoSmithKline, has been mired in controversy for several years because of analyses of data showing that rosiglitazone may increase the risk of MI or death. The Food ...
